{"name":"Fondazione per la Medicina Personalizzata","slug":"fondazione-per-la-medicina-personalizzata","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Oncology Drugs","genericName":"Oncology Drugs","slug":"oncology-drugs","indication":"Other","status":"phase_2"},{"name":"Vismogedib","genericName":"Vismogedib","slug":"vismogedib","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Oncology Drugs","genericName":"Oncology Drugs","slug":"oncology-drugs","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vismogedib","genericName":"Vismogedib","slug":"vismogedib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPYURiRUNvd25hQ0haZm15bDV3UjNSaGhaMmgwc2JHSmpyZjN5WXNFLS1qQUFZS0psbmYyWkJON1ZwdFlvNDUySmgyYlFkWDVEaUZKamRKbGNpaGpSN3laNEZNSjhlVUNMeHhIR001VHNRUURNVnE0OUZrb2xUZ3VfNzBJeTVIWDNGS0cwek5FLW85MF93YVYyZE9IcFl6RklQd2s0dlRHNl9nVjI5WHdLMlFidGFsUG04d1ZRZ0hkdWE?oc=5","date":"2026-03-25","type":"trial","source":"Stock Titan","summary":"AI will sift 400-patient cancer trial data for responder subgroups - Stock Titan","headline":"AI will sift 400-patient cancer trial data for responder subgroups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1mZnhVdTgwMTNPMUNkMHNaNnpXN0JENGxBZ3BkeHViaWpEMkpOWlI2eE5WeU4wcEtTTEZDc1Q3eGd6VXViNV8tSmw2bDRsaUtaWk9jd3VKUk5kcW1QZ1hB?oc=5","date":"2025-09-29","type":"trial","source":"Nature","summary":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial - Nature","headline":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}